Next, we are planning to study the correlation between cytoplasmic PPARγ expression and patient survival further, and develop a MEK-ERK pathway signature in breast cancer cells that could be used for patient selection for treatment with a MEK inhibitor. This evidence concerns the gene MAP2K7 and breast cancer.